-
In this study, Blackshear and colleagues report on their experience with thoracoscopic surgical techniques to close the left atrial appendage as prophylaxis against stroke in patients with atrial fibrillation.
-
The efficacy and safety study of oral direct thrombin Inhibitor Ximelagatran Compared with Dose-Adjusted Warfarin in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) was presented by Dr. Jonathan Halperin.
-
Studies of selected patients with ischemic cardiomyopathy have shown improved survival with the use of prophylactic implantable cardioverter
defibrillators (ICD). Thus, DEFibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) was designed to test the survival benefit of ICDs in patients with heart failure but without coronary artery disease.
-
Dr. Joseph Ornato presented the Public Access Defibrillation (PAD) study, which evaluated the efficacy of out-of-hospital cardiac arrest treatment by cardiopulmonary resuscitation (CPR) alone vs CPR plus
use of an automatic external defibrillator (AED) performed by trained laypersons.
-
In the Valsartan in Acute Myocardial Infarction Trial (VALIANT) the angiotensin II receptor blocker (ARB) valsartan (V) was evaluated in 14,703 high-risk acute MI patients to determine its efficacy and safety
profile compared to the ACE inhibitor captopril (C).
-
Reversing Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) is a prospective, randomized, controlled trial assessing the effectiveness of an intensive or aggressive lipid-lowering approach
(atorvastatin 80 mg) to a moderate one (pravastatin 40 mg).
-
-
The results of genetic analysis of a strain of S aureus with high-level resistance to vancomycin suggest that this resistance was the consequence of genetic transfer from a VRE to an MRSA, each present in and on the unfortunate patient who served as the incubator.
-
In a multicenter study of occupational HIV exposures, 38% of source patients had genotype mutations associated with resistance to antiretroviral drugs. Recent antiretroviral treatment history was highly associated with resistance.
-
The following summary of selected abstracts from 3 meetings will be published in multiple parts. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) met in Chicago September 14-17, 2003.
